MBCC

MIAMI BEACH – Breast surgeons can help relieve a “medical education crisis” by advising breast cancer patients about the implications of genetic testing results. The crisis continues to worsen given the remarkable rise in precision medicine and the limited number of genetic counselors in the United States, Patrick W. Whitworth, MD, said at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

Breast surgeons are qualified to help counsel patients, and, in fact, already order more than half of breast cancer genetic sequencing, a specialist survey reveals, said Dr. Whitworth, director of the Nashville (Tenn.) Breast Center, in a video interview.

At the same time, the one genotype–one phenotype paradigm for cancer genetics is rapidly shifting to testing patients for a whole panel of mutations simultaneously. Breast surgeons can partner with genetic counselors to support and expand the reach of this vital medical testing and counseling to more patients, he added.

Dr. Whitworth receives research grant support from and is a shareholder in Targeted Medical Education. He is also a shareholder in Advantage Consulting and Education.

MIAMI BEACH – Breast surgeons can help relieve a “medical education crisis” by advising breast cancer patients about the implications of genetic testing results. The crisis continues to worsen given the remarkable rise in precision medicine and the limited number of genetic counselors in the United States, Patrick W. Whitworth, MD, said at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

Breast surgeons are qualified to help counsel patients, and, in fact, already order more than half of breast cancer genetic sequencing, a specialist survey reveals, said Dr. Whitworth, director of the Nashville (Tenn.) Breast Center, in a video interview.

At the same time, the one genotype–one phenotype paradigm for cancer genetics is rapidly shifting to testing patients for a whole panel of mutations simultaneously. Breast surgeons can partner with genetic counselors to support and expand the reach of this vital medical testing and counseling to more patients, he added.

Dr. Whitworth receives research grant support from and is a shareholder in Targeted Medical Education. He is also a shareholder in Advantage Consulting and Education.

MIAMI BEACH – Breast surgeons can help relieve a “medical education crisis” by advising breast cancer patients about the implications of genetic testing results. The crisis continues to worsen given the remarkable rise in precision medicine and the limited number of genetic counselors in the United States, Patrick W. Whitworth, MD, said at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

Breast surgeons are qualified to help counsel patients, and, in fact, already order more than half of breast cancer genetic sequencing, a specialist survey reveals, said Dr. Whitworth, director of the Nashville (Tenn.) Breast Center, in a video interview.

At the same time, the one genotype–one phenotype paradigm for cancer genetics is rapidly shifting to testing patients for a whole panel of mutations simultaneously. Breast surgeons can partner with genetic counselors to support and expand the reach of this vital medical testing and counseling to more patients, he added.

Dr. Whitworth receives research grant support from and is a shareholder in Targeted Medical Education. He is also a shareholder in Advantage Consulting and Education.

MIAMI BEACH – Hormonal ablation is a mainstay of therapy for women with hormone receptor–positive breast cancer. A significant proportion of patients, however, are either initially refractory to hormonal therapy or acquire resistance to it over time.

The difficulty for patients with breast cancer and for the physicians who treat them is that there are no simple answers to the question of which patients can continue to benefit from endocrine monotherapy. Are there adequate biomarkers for optimal follow-on therapy when a patient experiences disease progression, and what is the optimal sequence of targeted therapy with endocrine inhibitors, disrupters, or other agents?

In a video interview at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource, William J. Gradishar, MD, of Northwestern University, Chicago, discusses strategies for combating resistance to endocrine ablative therapy, and describes how new therapies and new treatment strategies are being incorporated into National Comprehensive Cancer Network breast cancer guidelines.

Dr. Gradishar reported having no clinical disclosures.

MIAMI BEACH – Hormonal ablation is a mainstay of therapy for women with hormone receptor–positive breast cancer. A significant proportion of patients, however, are either initially refractory to hormonal therapy or acquire resistance to it over time.

The difficulty for patients with breast cancer and for the physicians who treat them is that there are no simple answers to the question of which patients can continue to benefit from endocrine monotherapy. Are there adequate biomarkers for optimal follow-on therapy when a patient experiences disease progression, and what is the optimal sequence of targeted therapy with endocrine inhibitors, disrupters, or other agents?

In a video interview at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource, William J. Gradishar, MD, of Northwestern University, Chicago, discusses strategies for combating resistance to endocrine ablative therapy, and describes how new therapies and new treatment strategies are being incorporated into National Comprehensive Cancer Network breast cancer guidelines.

Dr. Gradishar reported having no clinical disclosures.

MIAMI BEACH – Hormonal ablation is a mainstay of therapy for women with hormone receptor–positive breast cancer. A significant proportion of patients, however, are either initially refractory to hormonal therapy or acquire resistance to it over time.

The difficulty for patients with breast cancer and for the physicians who treat them is that there are no simple answers to the question of which patients can continue to benefit from endocrine monotherapy. Are there adequate biomarkers for optimal follow-on therapy when a patient experiences disease progression, and what is the optimal sequence of targeted therapy with endocrine inhibitors, disrupters, or other agents?

In a video interview at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource, William J. Gradishar, MD, of Northwestern University, Chicago, discusses strategies for combating resistance to endocrine ablative therapy, and describes how new therapies and new treatment strategies are being incorporated into National Comprehensive Cancer Network breast cancer guidelines.

Dr. Gradishar reported having no clinical disclosures.

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD

Sessions will explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy.

FROM MBCC (FRONTLINE MEDICAL NEWS) – Oncology Practice will be on site this coming week at the Miami Breast Cancer Symposium in Miami Beach, reporting on the latest in multidisciplinary management of breast cancer patients. Sessions will highlight updates in systemic therapy, immunology and immunotherapy, and overcoming therapeutic resistance, as well as explore treatment controversies, such as omitting anthracyclines, extended-field radiation therapy, and who should be receiving extended hormonal therapy. The symposium, hosted by Physicians’ Education Resource, begins Thursday, March 9. Our team will provide daily coverage of the following presentations and more:
 

Overcoming Resistance to HER2 Targeted Therapy

Mark D. Pegram, MD



Overcoming Resistance to Endocrine Ablative Therapy

William J. Gradishar, MD



Medical Crossfire: Is Extended Field Radiation Therapy Ready for Prime Time?

Lawrence J. Solin, MD, & Thomas A. Buchholz, MD



Raising the Therapeutic Index for HER2+ Targeted Therapy: Can We Safely Omit

Anthracyclines?

Sara Hurvitz, MD



Update on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

Debu Tripathy, MD



Update on PARP Inhibitors in Breast Cancer

Kimberly L. Blackwell, MD



Update on Immunology and Immunotherapy in Breast Cancer

Elizabeth Mittendorf, MD, PhD



Medical Crossfire: Is Extended Hormonal Therapy Required for Everyone?

William J. Gradishar, MD, & Sara Hurvitz, MD